Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 29 min 13 sec ago

National Call to Companies for Applications to Present at the OBIO 2019 Niagara Investment Summit

Thu, 13/12/2018 - 19:00
TORONTO--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;#healthsciencelt;/agt;--The national call for applications from health science companies to present at the OBIO 2019 Niagara Investment Summit is now open, Feb 20-22, 2019.

QxMD Software Appoints Ian Palmer to Lead Pharmaceutical Solutions Division

Thu, 13/12/2018 - 15:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;#CMElt;/agt;--Information industry veteran to guide life sciences revenue acquisition efforts for the company’s healthcare professional content engagement platform

Generex Biotechnology Partner Olaregen Therapeutix Sponsors Annual Meeting of Innovations in Wound Healing

Thu, 13/12/2018 - 09:00
MIRAMAR, Fla.--(BUSINESS WIRE)--Generex Biotechnology Corporation (OTCQB:GNBT) announced today that Olaregen Therapeutix, a regenerative medicine company contracted to become a subsidiary of Generex, was a co-sponsor of the Annual Meeting of Innovations in Wound Healing (IWH) held December 7 – 9, 2018 in Key West, Florida and attended by over 150 influential clinicians and researchers. Olaregen also hosted an Advisory Board Meeting attended by esteemed influencers in the specialties of Vascular

Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease

Thu, 13/12/2018 - 09:00
BOSTON--(BUSINESS WIRE)--Health Canada grants market authorization for ORKAMBI® (lumacaftor/ivacaftor) for children with cystic fibrosis aged 2 to 5 years old.

Tilray® Announces International Advisory Board

Thu, 13/12/2018 - 01:00
NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ:TLRY), a global pioneer in cannabis production and distribution, today announced the formation of its International Advisory Board, an esteemed group of business and government leaders who will provide guidance to Tilray’s executive team and Board of Directors as the company pursues its aggressive global growth strategy. “We are honored to welcome this impressive group of distinguished leaders to the Tilray team,” says Brendan Ken

Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate

Wed, 12/12/2018 - 09:00
LAVAL, Quebec--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;#Altascienceslt;/agt;--Altasciences recently completed an important First-in-Human (FIH), Phase I, integrated adaptive clinical trial, including single and multiple ascending doses (SAD and MAD), Project Management, Bioanalysis, and Medical Writing, for sponsor Bellus Health. Altasciences’ contributions to the positive top-line results were significant. From recruitment of 90 subjects to management of all relevant aspects of this important FIH trial, Altasciences used a flexible and ad

Halo Labs Announces Strategic Partnership in Lesotho Africa

Wed, 12/12/2018 - 09:00
TORONTO--(BUSINESS WIRE)--Halo Labs announces strategic partnership with a Bephelo Bioscience, a cannabis company in Lesotho Africa

2019 Catalyst Award for Top New Hire Now Accepting Applications

Tue, 11/12/2018 - 10:00
OTTAWA, Ontario--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;#HRlt;/agt;--The award showcases employees who have contributed to the growth of Canada’s bio-economy while highlighting biotech companies as Employers of Choice.

Versant Ventures Launches Black Diamond Therapeutics

Tue, 11/12/2018 - 09:00
BASEL, Switzerland & TORONTO--(BUSINESS WIRE)--Black Diamond Therapeutics, a biotechnology company developing a new type of precision medicine for cancer, came out of stealth mode today with a $20 million Series A financing exclusively from founding investor Versant Ventures. Black Diamond is the first company launched out of Ridgeline, Versant’s Discovery Engine based in Basel, Switzerland, and has a unique platform capable of prosecuting allosteric mutant oncogenes. Oncogenes are activated by

Analytics 4 Life® and Actelion Enter Research Agreement to Develop New Diagnostics for Pulmonary Hypertension

Tue, 11/12/2018 - 08:00
RESEARCH TRIANGLE PARK, N.C. & TORONTO--(BUSINESS WIRE)--Analytics 4 Life, a digital health company dedicated to improving existing diagnostic pathways, and Actelion Pharmaceuticals Ltd., today announced a collaborative agreement to investigate the use of Analytics 4 Life’s diagnostic imaging technology in pulmonary hypertension. The first 500-person clinical study has been initiated for this serious, life-threatening condition affecting millions of people worldwide. Analytics 4 Life seeks to u

Acerus Announces Results of Phase 1 Clinical Trial with a Proprietary Intranasal Formulation of a Tetrahydrocannabinol-Rich Cannabis Oil

Tue, 11/12/2018 - 08:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) is today providing results of a Phase 1 clinical trial (the “trial”) testing a proprietary intranasal formulation of a tetrahydrocannabinol (“THC”)-rich cannabis oil in healthy volunteers. The THC trial, previously announced on October 24, 2018, involved 12 overnight-fasting, healthy subjects with prior cannabis experience. Each subject randomly received one 5mg dose of cannabis oil orally and an

Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of Directors

Mon, 10/12/2018 - 09:00
GUILFORD, Conn.--(BUSINESS WIRE)--lt;a href="" target="_blank"gt;$BIOAFlt;/agt; lt;a href="" target="_blank"gt;#BBBlt;/agt;--Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced the appointment of Deborah A. Rathjen, B.Sc. (Hons), Ph.D.,

NanoSphere Forms Strategic Partnership to Launch Evolve Products in Mexico

Mon, 10/12/2018 - 08:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--NanoSphere signs key agreement for distribution of cannabis and CBD products in Mexico, as country prepares for legalization.

Zymeworks Submits Investigational New Drug (IND) Application for ZW49 and Presents IND-Enabling Studies at the San Antonio Breast Cancer Symposium

Sat, 08/12/2018 - 09:00
VANCOUVER, Canada--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, presented IND-enabling data for ZW49, a novel biparatopic HER2-targeted ADC, at the San Antonio Breast Cancer Symposium in San Antonio, TX. “These data highlight the potential efficacy of ZW49 versus leading HER2 ADCs and demonstrate the power of combining our therapeutic platforms to achieve greater efficacy and tolerability, thereby increasin

Contextual Genomics’ Scientific Founders Recognized for their Exceptional Research Contributions

Fri, 07/12/2018 - 11:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--#cancergenomics--Contextual Genomics Inc., a leading Canadian cancer genomics company headquartered in Vancouver, Canada, announces that its Scientific Founders, Drs. Samuel Aparicio, David Huntsman and Sohrab Shah, have been recognized by Web of Science (Clarivate Analytics) for their exceptional research performance, as determined by production of multiple highly cited papers that rank in the top 1% by citations for field and year. Of the world population of scien

Ontario Bioscience Innovation Organization Announces a National Call to Companies for Applications for the 2019 Niagara Investment Summit

Fri, 07/12/2018 - 10:00
TORONTO--(BUSINESS WIRE)--#healthscience--The Ontario Bioscience Innovation Organization (OBIO®) is announcing a national call for applications from health science companies who are seeking Series A or beyond investments to participate in the OBIO 2019 Niagara Investment Summit on February 20-22, 2019. The OBIO 2019 Niagara Investment Summit will bring 30 of Canada’s most promising health science companies to Niagara-on-the-Lake to present to and meet with global investors. The Summit will feature keynote pres

QxMD Software’s Content Engagement Platform Tops 200 Million Annual Views by Healthcare Professional (HCP) Members

Thu, 06/12/2018 - 13:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--#CME--QxMD Pathways sets new membership engagement milestone, exceeds 200 million mark for annual aggregate views across mobile and web platform channels.

Tilray® Announces Support for Study Led by University of Sydney Examining the Effects of Driving under the Influence of Cannabis

Thu, 06/12/2018 - 09:00
NANAIMO, British Columbia--(BUSINESS WIRE)--Tilray, Inc. (NASDAQ: TLRY), a global leader in cannabis research and production, today announced that it partnered with researchers at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney to complete a study examining the effects of cannabis on driving and cognitive function. “The Effects of Medicinal Cannabinoids on Driving” study was a double blind, placebo-controlled study that compared the effects of two varieties of ca

FSD Pharma Announces Collaboration and License Agreement with World Class Extractions

Thu, 06/12/2018 - 08:00
TORONTO--(BUSINESS WIRE)--#FSDDF--FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9), which, through its wholly-owned subsidiary, FV Pharma Inc. (“FV Pharma”), is a licensed producer pursuant to the Cannabis Act, announced today that it has entered into a definitive Collaboration and License Agreement (the “Agreement”) with World Class Extractions Inc. (“World Class”), a company that has developed a unique extraction process designed to produce quality, potent cannabis extracts. World

FSD Pharma Congratulates Partner Canntab on Launch of Research Partnership with Leading Orthopaedic Surgeon Dr. Don Garbuz, M.D.

Wed, 05/12/2018 - 14:00
TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) today congratulated strategic partner Canntab Therapeutics Limited (“Canntab”) (CSE: PILL) (FSE: TBF1) on the launch of a research partnership with leading orthopaedic surgeon Dr. Don Garbuz, M.D. Dr. Garbuz will be the lead investigator on a clinical research study at the University of British Columbia subject to the University’s approval that aims to show the potential for reduction or elimination o